Center-Authored Papers

Filters: Author is Livingston, Robert  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
B
Brown-Glaberman U, Marron M, Chalasani P, Livingston R, Iannone M, Specht J, Stopeck AT.  2016.  Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer. Disease Markers. 2016:1-7. Abstract
C
Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow JR, Hortobagyi GN, Livingston R.  2008.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.. Clinical breast cancer. 8(6):511-5. Abstract
D
Dunnwald L, Doot R, Gralow J, Ellis G, Livingston R, Linden H, Specht J, Gadi V, Kurland B, Mankoff D.  2009.  PET tumor metabolism in locally advanced breast cancer patients: Predicting outcome after neoadjuvant chemotherapy by kinetic analysis of FDG PET. Society of Nuclear Medicine Annual Meeting Abstracts. 50:24.
H
Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C et al..  2010.  Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.. The American journal of pathology. 176(4):1639-47. Abstract
R
Robins HS, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, Carlson CS, Nepom G, Yee C, Cerosaletti K.  2012.  Ultra-sensitive detection of rare T cell clones.. Journal of immunological methods. 375(1-2):14-19. Abstract
T
Tubbs R, Barlow WE, Budd TG, Swain E, Porter PL, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle J et al..  2009.  Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(24):3881-6. Abstract